Every article lists the sources it was built from, published alongside the story, so you never have to take our word for it.
Looking for the news? Read Via News at via.news, or in Portuguese, Spanish and French.
Les biotechs cotées avancent en essais cliniques (Scribe, Vor, Akari) pendant que la tech américaine subit une séance à 1 000 milliards de dollars de pertes. Les bilans vérifiés d'Incyte montrent ce qui distingue les sociétés financées de celles qui dépendent du marché.
Scribe, Vor, Akari y BioArctic reportaron avances en el cuarto trimestre de 2026, justo cuando una caída de 1 billón de dólares en tecnología enfría el apetito por el riesgo. Las cifras de caja de Incyte, verificadas contra la SEC, muestran qué significa tener margen.
Scribe, Vor e Incyte tiveram avanços no 4.º trimestre de 2026, mas a queda de 1 trilhão de dólares nas tecnológicas pode encarecer o financiamento do setor. Os dados da Incyte (registos na SEC) e os comunicados das empresas sustentam a análise. O dossiê não traz dados específicos de Brasil ou Portugal.
Scribe, Vor, Akari and Incyte reported progress in Q4 2026, while a $1 trillion tech selloff signalled tighter risk appetite. Stockholm-listed BioArctic shows what commercial-stage income looks like. Every figure is traced to a filing, a press release or a dated event.
Biotechs are reporting real progress while AI is being built into the work, but the AI funding mood turned cautious in late October. Via News checked company releases and SEC-sourced Incyte figures. The sourced evidence for an AI-biotech link is thin, and we say where.
Incyte's SEC-filed cash shows how lumpy biotech balance sheets are, while Scribe, Vor, Akari and BioArctic reported progress. A late-October tech selloff and a lower OpenAI funding target make financing harder to assume. Sources vary widely in reliability, and we show how much.
Anyone can repeat a public number. The hard part is checking it against the document it came from, at scale, every day, and keeping the record of how it changed. That checking is the newsroom.
Claims are matched against the original filing, release or document and checked against it, not paraphrased from a headline. What doesn't hold up, we flag.
We keep the full history of what was believed and when. Ask what the record said on any past date and get the answer as it stood.
Every check is also a datum about the source. Over time we learn which sources hold up: a private signal, never a public accusation.
When two sources disagree, we show the conflict instead of silently picking one. Trust comes from showing the seams.
Read the method in full at via.news/methodology. Every article page carries its sources as machine-readable citation data: free, no key, no account.
What we verified, what changed, and where the sources disagreed, in English or Portuguese.
The same verification runs across every property. Portuguese, Spanish and French editions are not translations of an English feed: they are their own newsrooms on the same engine.
Entities, facts, claims, contradictions and verification, with provenance, point-in-time queries and a free key. For developers and analysts who need the data rather than the reporting. We don't sell it here.
Syndication, corrections, or a story you think we should be checking? send it through the contact form. We reply from a monitored inbox, usually within one working day.
Essays and analysis carry the byline LM Salvado.